Clinical Trials

BOSTON — Eculizumab significantly reduced disease severity and improved quality of life at 26 weeks in adolescents with refractory generalized myasthenia gravis, according to a presenter at the American Academy of Neurology annual meeting.

BOSTON – Treatment with once-daily atogepant significantly reduced monthly migraine days in adults with episodic migraine compared with placebo, according to preliminary data presented at the American Academy of Neurology annual meeting.

Myrtelle Inc. has reported promising 6-month trial data for a recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease.

Healio spoke with Ahmed Elkhanany, MD, about where future research on metastatic triple-negative breast cancer should focus.

Healio’s top stories on Parkinson’s disease in the first portion of 2023 include an FDA inquiry into a treatment pump, adjunctive therapy for carbidopa/levodopa and results from several clinical trials. Here’s what you may have missed:

More than one-third of adults receiving tirzepatide in clinical trials experience gastrointestinal adverse events, but adverse events leading to drug discontinuation were rare, according to study data.

Continuous treatment with avalglucosidase alfa, or after a switch from alglucosidase alfa, maintained respiratory function and functional endurance in patients with late-onset Pompe disease, with no new safety concerns reported.

Walgreens and Prothena have announced a partnership to expand patient identification and recruitment for Prothena’s ongoing study of PRX012, an investigational anti-amyloid beta antibody for the treatment of Alzheimer’s disease.

Adding once-daily opicapone 50 mg to carbidopa/levodopa therapy helped achieve and maintain plasma concentrations of levodopa in patients with Parkinson’s disease, according to research in Clinical Neuropharmacology.

Merck KGaA announced the FDA has paused the initiation of new patients on evobrutinib for relapsing-remitting MS, as well as those with less than 70 days exposure to the treatment in the United States.